News | June 25, 2019

Pharmacy Times Continuing Education Presents The American Journal Of Managed Care (AJMC®) Payer And Specialty Pharmacy Forum: Improving The Adoption Of Oncology Biosimilars In Practice


Pharmacy Times Continuing Education™ (PTCE), a leader in continuing education for retail, health-system, managed care, and specialty pharmacists, launches The American Journal of Managed Care® (AJMC®) Payer and Specialty Pharmacy Forum: Improving the Adoption of Oncology Biosimilars in Practice. The activity is jointly presented by the Center for Biosimilars®, a resource for emerging technologies with a focus on improving critical thinking in the field to impact patient outcomes.

“Our Payer and Specialty Pharmacy Forum is designed to educate managed care professionals and specialty pharmacists about the utilization of biosimilars in oncology,” saidJim Palatine, RPh, MBA, president of PTCE. “The Forum is a nationally recognized health care communications platform fueled by debate, discussion, and interactive peer-exchange on important clinical issues to improve practices and patient care.”

The AJMC® Payer and Specialty Pharmacy Forum features an expert faculty panel including an oncologist, an oncology pharmacy clinical specialist, and an oncology managed care pharmacist who collaboratively review biosimilars as treatment options in the care of patients with cancer, regulations that govern the approval and utilization of biosimilar agents, challenges that have been encountered with the recent advent of biosimilar products, and potential benefits of biosimilars that warrant their adoption in clinical practice. The panel also addresses how pharmacists play a vital role in educating the healthcare team and patients as well as developing solutions to increase adoption of biosimilars.

The expert faculty panel includes:

  • Leigh M. Boehmer, Pharm.D., BCOP, medical director, education, Association of Community Cancer Centers.
  • Adam Brufsky, M.D., Ph.D., professor of medicine, associate chief for the division of hematology/oncology, codirector of the Comprehensive Breast Cancer Center and associate director of clinical investigations, University of Pittsburgh.
  • Jeremy Whalen, Pharm.D., BCOP, specialty clinical program director of oncology, Prime Therapeutics.

This activity is accredited by the Accreditation Council for Pharmacy Education for 1.5 contact hours and is supported by educational grants from Merck Sharp & Dohme Corp. and Amgen.

For more information and to participate, click here.

About Pharmacy Times Continuing Education™
Pharmacy Times Continuing Education™ (PTCE) is a leader in continuing education for retail, health system, managed care and specialty pharmacists. PTCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (CPE). PTCE’s print, online and live CPE activities are designed to help improve the knowledge, competence and skills of pharmacists so they are better prepared to provide the highest quality of pharmacy care to the patients they serve and to the physicians they assist as part of a multidisciplinary treatment and management team. To learn more about the educational activities sponsored by PTCE, visit

About TheAmerican Journal of Managed Care®
The American Journal of Managed Care ® (AJMC®) is a multimedia peer-reviewed, Medline-indexed journal that keeps readers on the forefront of health policy by publishing research relevant to industry decision-makers as they work to promote the efficient delivery of high-quality care. is the essential website for managed care professionals, distributing industry updates daily to leading stakeholders. Other titles in the AJMC® family include The American Journal of Accountable Care® and two evidence-based series, Evidence-Based Oncology™ and Evidence-Based Diabetes Management™. These comprehensive offerings bring together stakeholder views from payers, providers, policymakers and other industry leaders in managed care. To order reprints of articles appearing in AJMC® publications, please contact Gil Hernandez at 609-716-7777, ext. 139.

About The Center for Biosimilars®
The Center for Biosimilars® is a digital resource that serves as a platform for health economic experts, managed care professionals, key clinical specialists and other authoritative industry voices, to share information on emerging technologies, with a focus on improving critical thinking in the field to affect patient outcomes. The Center for Biosimilars®, which was cited in a United States Senate testimony on drug prices and out-of-pocket costs for rheumatoid arthritis drugs, discusses the current landscape for advanced health care management.

Copyright Business Wire 2019